Monday, December 15, 2008
Signs of wrenching change for the industry were unmistakable even before the economic crisis. Signs of wrenching change for the industry were unmistakable even before the economic crisis. While the healthcare sector is not destined for an economic rousting as acute as others, pharma will have a somewhat difficult road ahead: Long-term investment in R&D is likely to plummet as venture capital shrinks and stocks depress. Fewer new drugs in the market will have serious implications for innovation and profits.
Read the full article
here.